When and How to Use Somatostatin Analogues - 10/08/18
Résumé |
Long-acting depot formulations of the currently available somatostatin analogues are considered the first-line treatment for control of hormonal excess by hormone-producing neuroendocrine tumors of the gastrointestinal tract and pancreas. These drugs are currently also considered the first-line treatment for tumor control of both hormone-producing and non–hormone-producing neuroendocrine tumors of the gastrointestinal tract and pancreas. These drugs need coupling and interaction with specific somatostatin receptor subtypes, which are expressed on the cells of neuroendocrine tumors of the gastrointestinal tract and pancreas.
Le texte complet de cet article est disponible en PDF.Keywords : Somatostatin, Receptor, Octreotide, Lanreotide, Pasireotide, Neuroendocrine
Plan
| Disclosure Statement: The author has served on advisory boards for Novartis, Ipsen, and Advanced Accelerator Applications. The author has received research support from Novartis and Ipsen. |
Vol 47 - N° 3
P. 549-555 - septembre 2018 Retour au numéro
Article précédent
- Molecular Genetic Studies of Pancreatic Neuroendocrine Tumors : New Therapeutic Approaches
- Mark Stevenson, Kate E. Lines, Rajesh V. Thakker
- New Treatments for the Carcinoid Syndrome
- Paul Benjamin Loughrey, Dongyun Zhang, Anthony P. Heaney
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?